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Background: It remains unclear whether concomitant use of omeprazole attenuates
platelet function in Asian patients with acute coronary syndromes (ACS) receiving
clopidogrel according to cytochrome P450 (CYP) 2C19 phenotype.
Methods: Stent implantation was performed in 177 patients with ACS receiving aspirin
100mg/day and clopidogrel 75mg/day. The platelet reactivity index (PRI) was determined
on admission and average 18 days of after stenting with VASP assay.
Results: On the basis of CYP2C19 genotype, 46 patients (26%) were classified as
extensive metabolizers (EM), 103 (58%) as intermediate metabolizers(IM), and 28 (16%)
as poor metabolizers (PM). There were no significant differences in baseline character-
istics among 3 phenotypes. At baseline, PRI was similar in patients with PPIs and those
without among 3 phenotypes. Among EM, patients with PPIs had higher PRI at 18 days
(4516 vs 3813%; P0.05) and the smaller PRI variation (-45vs-59%, p 0.01)
compared with those without. In contrast, there were no significant differences in PRI
(5518 vs 5315%) and the mean PRI variation (-35%vs-36%) in patients with PPIs and
those without among IM. Similar trends were found in PRI (6910 vs 738%) and the
mean PRI variation (-18vs-15%) among PM (pNS, respectively).
Conclusions: In ACS patients treated with clopidogrel, co-administration of omeprazole
attenuates platelet function in non-carriers, but not in CYP2C19 variant allele carriers.
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Background: Compared with Caucasians, East Asians have shown relatively lower risk
of ischemic events following percutaneous coronary intervention (PCI). The contribution
of multiple risk factors to the occurrence of peri-procedural myocardial infarction (PMI)
in East Asians remains controversial.
Methods: We sought to assess the influence of clinical or laboratory covariates on the
occurrence of PMI in these patients undergoing elective PCI. Stable patients (n  341)
undergoing elective PCI were enrolled. Pre-PCI platelet reactivity was measured by light
transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay. Inflammation
markers (WBC and C-reactive protein) and lipid profile were determined by standard
methods. PMI was defined according to Universal definition [a post-procedural increase
in cardiac biomarker (troponin I and CK-MB)  3 times the 99th percentile of the upper
reference limit]. PMI (defined by troponin I and CK-MB) occurred in 47 (13.8%) and 30
(8.8%) patients, respectively.
Results: There was no significant difference in adenosine diphosphate (ADP)-induced
platelet reactivity between patients with vs. without PMI. Patients with PMI (troponin I)
had higher levels of 6 g/mL collagen-induced platelet aggregation (PA) and VerifyNow
’BASE’ compared with those without PMI. In multivariate analysis, age, stent length, and
low-density lipoprotein (LDL) cholesterol were independent determinants of PMI
(troponin I). The combination of ’6 g/mL collagen-induced PA  40%’ 	 ’BASE 
318’ (odds ratio, 14.08; 95% confidence intervals, 1.68 to 111.11; P  0.015) or ’WBC
 6550/mm3’ 	 ’C-reactive protein  2.3 mg/L’ (odds ratio, 7.75; 95% confidence
intervals, 2.49 to 24.39; P  0.001) was associated with an increased risk of PMI
(troponin I). The greatest likelihood ratio was observed when cholesterol, inflammation
marker and platelet function were combined together.
Conclusions: This is the first study to demonstrate that heightened platelet responsive-
ness to collagen and thrombin may be a risk factor for myonecrosis in patients undergoing
elective PCI. The utility of the combining measures of platelet function, inflammation and
cholesterol to enhance risk stratification and thus facilitate person.
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Background: Cilostazol use in ACS patients reduces the risks of ischemic events and
restenosis in East Asians. Compared with Caucasians, East Asians have higher frequency
of CYP2C19 loss-of-function allele (*2 and *3). We compared the pharmacodynamic
effect of adjunctive cilostazol vs. high-dose clopidogrel in PCI-treated East Asians with
ACS according to CYP2C19 genotype.
Methods: ACS patients were assigned to either clopidogrel 150 mg/d (DOUBLE;
n139) or cilostazol 100 mg twice a day 	 clopidogrel 75 mg/d (TRIPLE; n136) on
top of aspirin. Platelet aggregation (PA) was measured at baseline and follow-up (
30-day) with conventional aggregometery and adjusted with known clinical covariates.
Primary endpoint was the level of 20 M ADP-induced PA at follow-up. HPR was
defined as 20 M ADP-induced PA  59%.
Results: During standard-dose clopidogrel, platelet measurements did not differ accord-
ing to individual CYP2C19 genotype between the groups (Fig. A). PA levels and the risk
of HPR increased across CYP2C19 genotype (p  0.174). At follow-up, TRIPLE vs.
DOUBLE showed significantly lower level of PAs irrespective of CYP2C19 genotype
(Fig. B). DOUBLE showed 27.3% of HPR risk, which was increased across CYP2C19
genotype (adjusted p  0.042), whereas TRIPLE effect was not significantly influenced
with CYP2C19 genotype (adjusted p  0.289). Similar trend was observed for
collagen-induced PA.
Conclusions: In PCI-treated East Asians presented with ACS, adjunctive cilostazol to
dual antiplatelet therapy exhibited favorable platelet measurements compared with
high-dose clopidogrel irrespective of CYP2C19 genotype.
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Background: Current guidelines recommend that pts undergoing coronary stenting
receive dual-antiplatelet therapy to prevent acute stent thrombosis. There is limited data on
platelet inhibition in pts presenting with cardiac arrest who require both acute coronary
stenting and therapeutic hypothermia (TH). We sought to determine the extent of platelet
inhibition in pts requiring TH who were treated with clopidogrel.
Methods: We prospectively recruited pts who presented with a cardiac arrest who
required TH and acute coronary stenting. The loading dose of clopidogrel was 600mg
followed by a maintenance dose of 75mg daily administered via a nasogastric tube.
Platelet function was tested at baseline, and at 4, 8, 24, 48, 72, 96 and 120 hrs from the
loading dose of clopidogrel. Platelet activity was analyzed with the VerifyNow point-of-
care rapid platelet function analyzer. Primary endpoint was the extent of platelet inhibition
as a function of time.
Results: We evaluated 8 consecutive patients who received coronary stents and
subsequently required TH. The results of the platelet testing are depicted in the figure
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